Surfactant apoprotein A (SP-A) in tracheal aspirates of newborn infants with RDS
- PMID: 1799120
- DOI: 10.1111/j.1442-200x.1991.tb01880.x
Surfactant apoprotein A (SP-A) in tracheal aspirates of newborn infants with RDS
Abstract
Human pulmonary surfactant contains four groups of apoproteins, SP-A, B, C and D. We determined the concentration of SP-A in the tracheal aspirate of newborn infants by a two-site simultaneous immunoassay with monoclonal antibodies, and used this assay to assess changes in surfactant in various clinical situations. SP-A concentrations were standardized per milligram of albumin in the aspirate. The ratio of SP-A/albumin (micrograms/mg) in tracheal aspirates of 18 preterm infants with respiratory distress syndrome (RDS), in which samples were obtained within 12 hours of birth, was significantly lower (0.2 +/- 0.1 microgram/mg, mean +/- S.D.) compared to a group of 20 non-RDS preterm infants of similar gestational age (15.8 +/- 7.4 micrograms/mg) (p less than 0.05). None of the RDS infants had a SP-A/albumin ratio above 1 microgram/mg within 12 hours of birth, but the ratio exceeded 5 micrograms/mg in all samples from non-RDS infants. The SP-A/albumin ratio significantly increased, however, at 48 to 72 hours after birth in infants with RDS (15.7 +/- 9.5 micrograms/mg). During the recovery phase of RDS, no difference was evident in the SP-A/albumin ratio in babies treated with artificial surfactant compared to those not treated.
Similar articles
-
Surfactant proteins and stable microbubbles in tracheal aspirates of infants with respiratory distress syndrome: relation to the degree of respiratory failure and response to exogenous surfactant.Eur J Pediatr. 1997 Feb;156(2):131-8. doi: 10.1007/s004310050571. Eur J Pediatr. 1997. PMID: 9039518
-
Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome.Thorax. 1996 Sep;51(9):907-13. doi: 10.1136/thx.51.9.907. Thorax. 1996. PMID: 8984701 Free PMC article. Clinical Trial.
-
Surfactant protein A in the course of respiratory distress syndrome.Eur J Pediatr. 1992 Aug;151(8):596-600. doi: 10.1007/BF01957730. Eur J Pediatr. 1992. PMID: 1505580
-
Choosing a right surfactant for respiratory distress syndrome treatment.Neonatology. 2009;95(1):1-5. doi: 10.1159/000151749. Epub 2008 Oct 2. Neonatology. 2009. PMID: 18832858 Review.
-
Synthetic surfactants with SP-B and SP-C analogues to enable worldwide treatment of neonatal respiratory distress syndrome and other lung diseases.J Intern Med. 2019 Feb;285(2):165-186. doi: 10.1111/joim.12845. Epub 2018 Nov 14. J Intern Med. 2019. PMID: 30357986 Review.
Cited by
-
Genetic disorders of surfactant dysfunction.Pediatr Dev Pathol. 2009 Jul-Aug;12(4):253-74. doi: 10.2350/09-01-0586.1. Pediatr Dev Pathol. 2009. PMID: 19220077 Free PMC article. Review.
-
Genetic variant associations of human SP-A and SP-D with acute and chronic lung injury.Front Biosci (Landmark Ed). 2012 Jan 1;17(2):407-29. doi: 10.2741/3935. Front Biosci (Landmark Ed). 2012. PMID: 22201752 Free PMC article. Review.
-
Collectins and ficolins in neonatal health and disease.Front Immunol. 2023 Dec 19;14:1328658. doi: 10.3389/fimmu.2023.1328658. eCollection 2023. Front Immunol. 2023. PMID: 38193083 Free PMC article. Review.
-
Genetic risk factors associated with respiratory distress syndrome.Korean J Pediatr. 2014 Apr;57(4):157-63. doi: 10.3345/kjp.2014.57.4.157. Epub 2014 Apr 30. Korean J Pediatr. 2014. PMID: 24868212 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical